Pharmaceutical group ยท United States
Regeneron
A group of 6 companies with 42 medicines in 7 countries.
Group structure
6 companies in 3 countries
Loading your pageโฆ
Loading your pageโฆ
Pharmaceutical group ยท United States
A group of 6 companies with 42 medicines in 7 countries.
6 companies in 3 countries
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine of every company in the group, current ones first.
1โ25 of 42
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| Dupixent300mg/2ml ยท Injection | Dupilumab | United States | Not marketed | 2017 |
| Dupixent100mg/0.67ml ยท Injection | Dupilumab | United States | Not marketed | 2021 |
| Dupixent200mg/1.14ml ยท Injection | Dupilumab | United States | Marketed | 2018 |
| DUPIXENT150mg/ml ยท Injectable | Dupilumab | United States | Marketed | 2017 |
| Dupixent200mg/1.14ml ยท Injection | Dupilumab | United States | Marketed | 2021 |
| Dupixent300mg/2ml ยท Injection | Dupilumab | United States | Marketed | 2020 |
| EVKEEZA1200mg/8ml | 345mg/2.3ml ยท Solution | Evinacumab | United States | Marketed | 2021 |
| EYLEA40mg/ml ยท Injectable | Aflibercept | United States | Marketed | 2011 |
| Eylea2mg/0.05ml ยท Injection | Aflibercept | United States | Marketed | 2018 |
| EYLEA HD8mg(0.07ml ยท Injectable | Aflibercept | United States | Marketed | 2023 |
| INMAZEB16.7mg/1ml ยท Solution | Atoltivimab, Odesivimab, Maftivimab | United States | Marketed | 2020 |
| Inmazeb483.3mg, 483.3mg, 483.3mg/14.5ml (33.33mg, 33.33mg, 33.33mg/ml) ยท Injection | Atoltivimab, maftivimab,, Odesivimab | United States | Marketed | 2021 |
| LIBTAYO350 mg / 7 ml ยท Solution | Cemiplimab | Canada | Marketed | 2019 |
| LIBTAYOConcentrato per soluzione per infusione | Cemiplimab | Italy | Authorised | |
| LIBTAYO350mg ยท Injectable | Cemiplimab | United States | Marketed | 2018 |
| Libtayo | Cemiplimab | EU (EMA) | Authorised | 2019 |
| Libtayo 350 mg concentraat voor oplossing voor infusieConcentraat voor oplossing voor infusie | Cemiplimab | Netherlands | Authorised | 2019 |
| LIBTAYO 350 MG CONCENTRADO PARA SOLUCION PARA PERFUSION350 mg ยท Concentrado para soluciรณn para perfusiรณn | Cemiplimab | Spain | Authorised | 2026 |
| LIBTAYO 350 MG CONCENTRADO PARA SOLUCION PARA PERFUSION350 mg ยท Concentrado para soluciรณn para perfusiรณn | Cemiplimab | Spain | Marketed | 2019 |
| Lynozyfic200mg/10ml (20mg/ml) ยท Injection | Linvoseltamab | United States | Marketed | 2025 |
| LYNOZYFICConcentrato per soluzione per infusione | Linvoseltamab | Italy | Authorised | |
| Lynozyfic | Linvoseltamab | EU (EMA) | Authorised | 2025 |
| LYNOZYFIC 200 mg concentraat voor oplossing voor infusieConcentraat voor oplossing voor infusie | Linvoseltamab | Netherlands | Authorised | 2025 |
| LYNOZYFIC 200 MG CONCENTRADO PARA SOLUCION PARA PERFUSION200 mg ยท Concentrado para soluciรณn para perfusiรณn | Linvoseltamab | Spain | Authorised | 2025 |
| LYNOZYFIC 5 mg concentraat voor oplossing voor infusieConcentraat voor oplossing voor infusie | Linvoseltamab | Netherlands | Authorised | 2025 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 20 | 20 | 0 | CompaniesAll medicines |
| Spain | 7 | 7 | 0 | CompaniesAll medicines |
| Netherlands | 6 | 6 | 0 | CompaniesAll medicines |
| European Union (EMA) | 4 | 3 | 1 | CompaniesAll medicines |
| Italy | 3 | 3 | 0 | CompaniesAll medicines |
| Canada | 1 | 1 | 0 | CompaniesAll medicines |
| Romania | 1 | 0 | 1 | CompaniesAll medicines |
Also in the registers of Brazil, France, United Kingdom
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Companies are grouped by Prognia from the names regulators publish; not an official corporate structure.
Source: European Medicines Agency (EPAR data).
Licence: EMA reuse policy (source acknowledgement required)
Fuente de la informaciรณn: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Source: BDPM (ANSM, HAS, UNCAM).
Licence: Licence Ouverte v1.0
Anvisa, official medicine/API manufacturer factual export, HTTP source version Fri, 09 Oct 2026 08:21:54 GMT, acquired 2026-10-09; exact unmodified native identifiers and fields preserved.
Licence: Brazil federal factual open-data reuse; Decreto 8777/2016 consolidated article 4 and third-party exceptions
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Fuente de la informaciรณn: Agencia Espaรฑola de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la informaciรณn: Agencia Espaรฑola de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
BDPM / ANSM, HAS and UNCAM; original URLs and each update date retained
Licence: BDPM exact Licence Ouverte v1.0 (October 2011)
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 1 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:47.757811+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_H_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:40 GMT; acquired 2026-10-13T17:21:06.034935+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.
Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim
Ministerul Sฤnฤtฤศii, Catalogul public naลฃional al preลฃurilor, 18 iunie 2021, downloaded 2026-10-08 from data.gov.ro; CC BY 4.0; structured factual adaptation, code whitespace trimmed only where explicitly recorded.
Licence: Creative Commons Attribution 4.0 International (CC BY 4.0)
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions
Report an error or request removalCorrections from the company itself are welcome.
Well-known pharmaceutical groups, each with all its companies.
Ranked by their number of medicines.